Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For? | American Society of Nephrology
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 ( SGLT2) Inhibitors: A State-of-the-Art Review - ScienceDirect
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits - American Journal of Cardiology
Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review | Cardiovascular Ultrasound | Full Text
Is an SGLT2 inhibitor right for your patient with type 2 diabetes? | Diabetes Hub
SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart | JACC: Basic to Translational Science
SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report - Kidney Medicine
PLOS ONE: The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
SGLT2 inhibitors: molecular design and potential differences in effect - Kidney International
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
SGLT2 Inhibitors: A New Class of Diabetes Medications
References in SGLT2 Inhibitor–associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis - Clinical Therapeutics
SGLT2 Inhibitors in Heart Failure: DAPA-HF & EMPEROR Trials
Comparison of SGLT2 inhibitor and GLP-1 receptor agonist as addition metformin or metformin plus sulfonylurea: systematic review with indirect comparison meta-analysis - Virtual Meeting | EASD
SGLT2 inhibitors: a narrative review of efficacy and safety
SGLT2 inhibitor - Wikipedia
JCI Insight - Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
UK Kidney Association releases guideline on SGLT2 inhibitor use - DiabetesontheNet
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications - The Lancet
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism | SpringerLink
IJMS | Free Full-Text | Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Summary of Heart Failure Outcomes in SGLT2 Inhibitor Clinical Studies | Radcliffe Cardiology
SGLT2 inhibitor dosing chart
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition - ScienceDirect
